<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307827</url>
  </required_header>
  <id_info>
    <org_study_id>291-418</org_study_id>
    <secondary_id>2005-003482-17</secondary_id>
    <nct_id>NCT00307827</nct_id>
  </id_info>
  <brief_title>Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, immunogenicity, and safety of various
      doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis
      (IVSR-UC) and to evaluate optimal dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study Canceled
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in each of the three visilizumab dose groups who respond to treatment in the dose-exploration portion of this study (Stage 1).</measure>
    <time_frame>Day 45</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of subjects in the three visilizumab dose groups</measure>
    <time_frame>During the course of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visilizumab low dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visilizumab middle dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visilizumab high dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visilizumab</intervention_name>
    <description>Visilizumab administered intravenously once per day for two days</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>NuvionÂ®; HuM291</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Eligible subjects will be considered for inclusion in this study if they meet all of the
        following criteria:

          -  Males and females, 18 years of age or older.

          -  Diagnosis of ulcerative colitis (UC), as verified by endoscopy performed within 60
             months prior to consent.

          -  Severe active disease, as defined by modified Truelove Witts severity index (MTWSI) &gt;=
             11 at consent, with a confirmatory MTWSI &gt;= 10 on or after the fifth consecutive day
             of intravenous (IV) steroids and within 1 day prior to randomization.

          -  Mayo score &gt;= 10 and Mayo mucosal subscore &gt;= 2 after a minimum of 3 consecutive days
             (ie, on or after the fourth consecutive day) of IV steroids.

          -  Adequate contraception from the day of consent through 3 months after the last dose of
             study drug.

          -  Negative serum pregnancy test at screening.

          -  Negative Clostridium difficile test within 10 days prior to randomization.

          -  Signed and dated informed consent and Health Insurance Portability and Accountability
             Act (HIPAA) if applicable.

        Exclusion Criteria

        Subjects will be ineligible for this study if they meet any one of the following criteria:

          -  UC requiring immediate intervention.

          -  History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis

          -  Presence of ileostomy.

          -  White blood cell count less than 2.5 x 10^3/mcL; platelet count less than 150 x
             10^3/mcL; or hemoglobin level less than 8 g/dL.

          -  Active medically significant infections, particularly those of viral etiology, eg,
             known cytomegalovirus (CMV) colitis. This includes any incidence of medically
             significant opportunistic infections within the past 12 months.

          -  Live vaccination within 6 weeks prior to randomization.

          -  Significant organ dysfunction, including cardiac, renal, liver, central nervous system
             (CNS), pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality.

          -  History or treatment of lymphoproliferative disorder (LPD) or malignancy within the
             past 5 years (excluding nonmelanoma skin cancer or carcinoma in situ of the cervix).

          -  Seropositivity for infection with human immunodeficiency virus (HIV-1), hepatitis B
             virus (HBV) surface antigen, or hepatitis C virus (HCV).

          -  Pregnancy or nursing.

          -  Treatment with a first dose of infliximab or another anti-TNF-a drug within 4 weeks of
             randomization, or treatment with a subsequent dose of an anti-TNF-a drug within 2
             weeks of randomization.

          -  Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to
             randomization.

          -  Treatment with any other investigational drugs or therapies within 60 days prior to
             randomization, except those mentioned in the two exclusion criteria above.

          -  Unwilling or unable to discontinue all UC drugs, except glucocorticoids and oral
             5-ASA, immediately prior to randomization.

          -  Nontherapeutic levels of chronic antiseizure medications in subjects with a prior
             history of seizures.

          -  Any condition that, in the investigator's opinion, makes the subject unsuitable for
             study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihail Obrocea, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71894</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71897</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71913</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71895</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71896</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71875</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71873</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72338</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72334</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72345</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72314</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71953</name>
      <address>
        <city>Nizhny-Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72315</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72342</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72368</name>
      <address>
        <city>Badalona - Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72366</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steroid-Refractory</keyword>
  <keyword>IVSR-UC</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

